Amicus Therapeutics (FOLD) is a commercial stage biopharma that is seeing huge sales growth of its one marketed product, Galafold, which treats Fabry disease. Sales of Galafold are expected to easily exceed $1 billion as are sales of Amicus' late-stage therapy for Pompe disease, AT-GAA. Despite this, Amicus currently has a market cap of just over $3 billion. In this article, I will provide an overview of the company and discuss why I think Amicus is a strong value proposition for long-term investors.
Galafold's Launch Has Been Impressive
Galafold is indicated to treat